Arpraziquantel: Difference between revisions

Arpraziquantel
Clinical data
Other names	(R)-Praziquantel
Drug class	Anthelmintic
ATC code	P02BA03 (WHO) ;
Identifiers
CAS Number	57452-98-9;
PubChem CID	445900;
DrugBank	DB11749;
ChemSpider	393394;
UNII	WF15T5925V;
KEGG	D12741;
ChEMBL	ChEMBL1235551;
PDB ligand	PZQ (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID80904739 ;
Chemical and physical data
Formula	C19H24N2O2
Molar mass	312.413 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [H][C@@]12CN(CC(=O)N1CCC1=CC=CC=C21)C(=O)C1CCCCC1;
	InChI InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2/t17-/m0/s1; Key:FSVJFNAIGNNGKK-KRWDZBQOSA-N;

Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 04:52, 20 December 2023

Arpraziquantel is a medication under investigation for the treatment of schistosomiasis.^[1]

Society and culture

Legal status

In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product arpraziquantel, intended for the treatment of schistosomiasis in young children.^[1] The applicant for this medicinal product is Merck Europe B.V.^[1] It is intended exclusively for markets outside the European Union.^[1]

Names

Arpraziquantel is the International nonproprietary name.^[2]

References

^ ^a ^b ^c ^d "Arpraziquantel". European Medicines Agency. 14 December 2023. Retrieved 20 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.

Zdesenko G, Mutapi F (September 2020). "Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models". PLoS Neglected Tropical Diseases. 14 (9): e0008649. doi:10.1371/journal.pntd.0008649. PMC 7518612. PMID 32976496.{{cite journal}}: CS1 maint: unflagged free DOI (link)

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Arpraziquantel-1] "Arpraziquantel". European Medicines Agency. 14 December 2023. Retrieved 20 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[2] World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.

[1]

[2]

Revision as of 04:52, 20 December 2023

Society and culture

Legal status

Names

References

Further reading